Exelixis, INC Form 4 insider transactions

Exelixis, Inc. Director George Poste reported the acquisition of 9,812 restricted stock units (RSUs) on May 29, 2025, as part of the company's equity incentive plan.

Exelixis, Inc. Director Jack L. Wyszomierski was granted 9,812 restricted stock units (RSUs) on May 29, 2025, which are set to vest in May 2026.

Exelixis, Inc. Director Maria C. Freire was granted 9,812 restricted stock units (RSUs) on May 29, 2025, as part of the company's equity incentive plan.

Exelixis, Inc. Director Stelios Papadopoulos was granted 9,812 restricted stock units (RSUs) on May 29, 2025, as part of his compensation, which are set to vest in May 2026.

Exelixis, Inc. Director Sue Gail Eckhardt was granted 9,812 restricted stock units (RSUs) on May 29, 2025, which will vest fully on May 29, 2026.

Exelixis, Inc. Director Julie Smith was granted 9,812 restricted stock units (RSUs) on May 29, 2025, as part of her compensation.

Patrick J. Haley, EVP, Commercial at Exelixis, Inc., reports the sale of 34,387 shares of common stock at an average price of $44.06.

Director Tomas J. Heyman reported the sale of 4,544 shares of Exelixis common stock at a price of $44.29 on May 21, 2025.

Director George Poste exercised stock options and sold shares of Exelixis, Inc. common stock on May 16, 2025.

Dana Aftab, CSO of Exelixis, sold shares to cover tax obligations related to vesting restricted stock units.

Christopher J. Senner, EVP and CFO of Exelixis, reports the disposition and acquisition of company stock, including shares withheld for tax obligations and the exercise and sale of stock options.

Director Stelios Papadopoulos exercised stock options and sold shares of Exelixis, Inc. on May 15, 2025.

Michael Morrissey, CEO of Exelixis, reports exercising stock options, share withholding for taxes, and gifting shares to a family trust.

Jeffrey Hessekiel, EVP & General Counsel of Exelixis, reports the disposition and acquisition of company stock, including shares withheld for tax obligations and sales on the open market.

Patrick J. Haley, EVP, Commercial at Exelixis, Inc., reports multiple transactions involving the company's common stock, including sales, option exercises, and tax-related share withholdings.

EVP Amy C. Peterson reports acquisition and disposal of Exelixis stock, including shares withheld for taxes and sales on the open market.

Dana Aftab, CSO/EVP of Discovery & Translational Research at Exelixis, reports the acquisition and disposal of common stock, including shares from the employee stock purchase plan and holdings in a 401(k) plan.

Amy C. Peterson, EVP of Product Development & Medical Affairs and CMO at Exelixis, Inc., received performance-based restricted stock units and disposed of common stock on March 31, 2025.

Michael Morrissey, CEO of Exelixis, reports the acquisition of performance-based restricted stock units and holdings in common stock through various means, including a family trust and a 401(k) plan.

A Form 4 filing reveals that Exelixis CSO Aftab Dana acquired performance-based restricted stock units and disposed of common stock, while also holding shares through the company's 401(k) plan.

Jeffrey Hessekiel, EVP & General Counsel of Exelixis, reports the acquisition of performance-based restricted stock units and adjustments to holdings in common stock and 401(k).

EVP, Commercial, Patrick J. Haley, reports acquisition of performance-based restricted stock units and adjustments to beneficial ownership of Exelixis, Inc. common stock.

Christopher J. Senner, EVP and CFO of Exelixis, reports the acquisition of performance-based restricted stock units and adjustments to holdings in common stock and 401(k).

Patrick J. Haley, EVP, Commercial at Exelixis, Inc., reports the sale of 10,000 shares of common stock at $38.80 per share, pursuant to a pre-arranged Rule 10b5-1 trading plan.

Director Julie Smith reports exercising stock options and selling shares of Exelixis, Inc. common stock.

Exelixis CEO Michael Morrissey reports acquisition of shares through vesting of restricted stock units and holdings through a family trust and 401(k).

Dana Aftab, CSO/EVP of Discovery & Translational Research at Exelixis, reports the acquisition of stock through restricted stock units (RSUs) and holdings in the company's 401(k) plan.

EVP, Commercial of Exelixis, Patrick J. Haley, reports the acquisition of 47,718 shares of common stock through the vesting of restricted stock units (RSUs).

Jeffrey Hessekiel, EVP & General Counsel of Exelixis, reports the acquisition of 52,192 shares of common stock through restricted stock units (RSUs) and the holding of 999 shares of common stock through a 401(k) plan.

EVP Amy C. Peterson reports the acquisition of 52,192 shares of Exelixis common stock through the vesting of restricted stock units (RSUs).